KG
PTCT icon

Kilter Group’s PTC Therapeutics PTCT Stock Holding History

Kilter Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.96K Hold
73
– – ﹤0.01% 625
2026
Q1 		$4.97K Sell
73
-3
-4% -$212 ﹤0.01% 620
2025
Q4 		$5.77K Buy
76
+44
+138% +$3.2K ﹤0.01% 477
2025
Q3 		$1.96K Sell
32
-2
-6% -$104 ﹤0.01% 665
2025
Q2 		$1.66K Buy
+34
New +$1.61K ﹤0.01% 675

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Kilter Group's PTCT Position: Q2 2026 in Review

Kilter Group held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 73 shares worth $5.96K. The position accounts for ﹤0.01% of the portfolio, ranked #625.

Kilter Group first reported a position in PTCT in Q2 2025 and has held it in 5 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Kilter Group held 73 shares of PTC Therapeutics worth $5.96K as of Q2 2026.
  • Kilter Group left its PTC Therapeutics share count unchanged in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Kilter Group's portfolio in Q2 2026, its #625 holding.
  • Kilter Group first reported a position in PTC Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.